Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Investments: 2020-2021

  • Xeris Biopharma Holdings' Long-Term Investments was N/A to $33.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $33.5 million, marking a year-over-year change of. This contributed to the annual value of $96.2 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Long-Term Investments of $33.5 million as of Q3 2021, which was down 65.18% from $96.2 million recorded in Q4 2020.
  • In the past 5 years, Xeris Biopharma Holdings' Long-Term Investments ranged from a high of $96.2 million in Q4 2020 and a low of $33.5 million during Q3 2021.
  • Over the past 2 years, Xeris Biopharma Holdings' median Long-Term Investments value was $64.8 million (recorded in 2020), while the average stood at $64.8 million.